John Hohneker, M.D.

Dr. John Hohneker brings 30 years of drug development and leadership experience within the biotech and pharmaceutical industry. He most recently served as President and CEO of Anokion and currently serves on the boards of Evelo Biosciences, Aravive, Trishula Therapeutics and Cygnal Therapeutics.

Prior to Anokion, he was President of Research and Development at FORMA Therapeutics Inc., where he guided the Company’s transition from a discovery-stage biotech to one with multiple programs in clinical trials. Prior to FORMA, he held leadership roles of increasing responsibility at Novartis AG, most recently as Senior Vice President and Global Head of Development for Immunology and Dermatology, where he led the development and registration of Cosentyx® and Ilaris®. During his tenure at Novartis, Dr. Hohneker also played a key role in the development, approval and commercialization of several products, including Gleevec®, Tasigna®, Zometa®, Afinitor® and Exjade®. Prior to joining Novartis, he held positions of increasing responsibility at Glaxo Wellcome and its legacy company, Burroughs Wellcome. He received a B.A. from Gettysburg College and an M.D. from Rutgers School of Biomedical and Health Sciences (formerly the University of Medicine and Dentistry of New Jersey-Rutgers Medical School). He completed his internship and residency in internal medicine and his fellowship in medical oncology at the University of North Carolina at Chapel Hill.